Notice of Results

16 March 2020

Notice of Results 2019

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal technology DermaSys® and currently focused on sexual health and pain, will announce its audited results for the year ended 31 December 2019 on Wednesday, 1 April 2020.

James Barder, Chief Executive Officer, Angela Hildreth, Finance Director/Chief Operating Officer, and Ken James, Executive Director and Head of R&D, will host a webcast for analysts on the day of the results, which will be made available within the investor centre section of the Company's website.

In light of growing concerns regarding COVID-19, the Company has decided to cancel its scheduled Investor Seminar, to be held on 26 March 2020. 

The Results webcast will now incorporate the Investor Seminar presentation which includes an extensive internal evaluation of the clinical data from the Phase 3 study ("FM57"), ongoing research and analysis of MED3000, as well as an update on regulatory discussions and insight into the erectile dysfunction market presented by Professor David Ralph, world leading expert in erectile dysfunction and male infertility and member of the Futura European KOL Advisory Panel.

For further information please contact:

Futura Medical plc

James Barder, Chief Executive

Angela Hildreth, Finance Director and COO

Email: Investor.relations@futuramedical.com 

Tel: +44 (0) 1483 685 670

www.futuramedical.com

Nominated Adviser and Sole Broker:

Liberum

Bidhi Bhoma/ Euan Brown/ Kane Collings

Tel: +44 (0) 20 3100 2000

For media enquiries please contact:

Optimum Strategic Communications

Mary Clark/ Eva Haas/ Hollie Vile

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 950 9144